Moreover, patients with the IASD placement showed a trend for improved New York Heart Association (NYHA) functional class and reduced HF hospitalization. 12 However, the phase 3 REDUCE LAP‐HF II trial involving 626 symptomatic HF patients with LVEF ≥40% and elevated resting or exercise PCWP failed to confirm better outcomes for IASD in cardiovascular death, non‐fatal ischaemic stroke, first and recurrent HF events, and health status compared with a sham procedure.
← all excerpts
Advances in device-based treatment of heart failure with preserved ejection fraction: evidence from clinical trials.
1
—
—